On April 15, 2013, Aurolife Pharma, LLC received FDA approval for the ANDA representing acetaminophen and codeine phosphate tablets. This authorization strengthens the market offering of this widely used analgesic by adding a generic alternative and providing a potential boost to the company's product portfolio.